Note 2022 $’000 2021 $’000 ASSETS Current Assets: Cash and cash equivalents 8 40,180 36,783 Trade and other receivables 9 3,066 3,261 Total current assets 43,246 40,044 Non-current assets: Property, plant and equipment 21 12 Total non-current assets 21 12 TOTAL ASSETS 43,267 40,056 LIABILITIES AND EQUITY Current liabilities: Trade and other payables 10 978 803 Derivative liabilities 11 700 – Total current liabilities 1,678 803 Total liabilities 1,678 803 EQUITY Share capital 12 167,740 167,578 Share option reserve 3,222 1,234 Currency translation reserve (10,680) (10,682) Accumulated deficit (118,693) (118,877) Total equity attributable to equity holders 41,589 39,253 TOTAL LIABILITIES AND EQUITY 43,267 40,056 The notes on pages 30 to 44 form part of these consolidated financial statements. For and on behalf of the Board of Directors who authorised the issue of these consolidated financial statements on 23 February 2023. CONSOL I DATED STATEMENT OF F I NANC I A L POS I T I ON A S AT 3 1 D E C EMB E R 2 0 2 2 Patrick Davies Non-Executive Chair Dr Trevor Scott Director Neuren Pharmaceuticals Limited Annual Repor t 2022 27
RkJQdWJsaXNoZXIy MjE2NDg3